Key facts
- Notable investors include Longshine Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Sitikangchen Pharmaceutical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Sitikangchen Pharmaceutical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sitikangchen Pharmaceutical Technology
Developer of radiopharmaceutical diagnostic and therapeutic agents designed to enable early detection and precision treatment of oncology and cardiovascular diseases. The company offers AI-driven molecular design, multidisciplinary radiopharmaceutical R&D capabilities, and integrated diagnostic-therapeutic pipelines, enabling healthcare providers and nuclear-medicine researchers to advance targeted imaging and treatment with higher accuracy and clinical impact.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Sitikangchen Pharmaceutical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sitikangchen Pharmaceutical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sitikangchen Pharmaceutical Technology in its N-PORT filings yet. We sweep new filings monthly.